Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex21-1.htm |
| EX-4.1 - EXHIBIT 4.1 - ENZON PHARMACEUTICALS, INC. | tm214060d1_ex4-1.htm |
| 10-K - FORM 10-K - ENZON PHARMACEUTICALS, INC. | tm214060d1_10k.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard L. Feinstein, Vice President-Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| February 23, 2021 | /s/ Richard L. Feinstein |
| Richard L. Feinstein | |
| Vice President - Finance and Chief Financial Officer | |
| (Principal Financial Officer) |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.